Thus, the efficient and specific beneficial effects of hCDR1 at the different checkpoints and on the various factors involved in lupus, as exemplified in the present study by its effect on one of the central cytokine, IFN-α, suggest a potential role for this tolerogenic peptide in the treatment of lupus patients. Here, IFNA1 is linked to systemic lupus erythematosus.